Let us begin with a midyear summary of index results that might surprise you in light of the triple-

COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno

Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Company has been added to the broad-marke

COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno

Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume.

COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno

Multi-organ system and quality-of-life benefits sustained through three and a half years 86% respons

COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno

Ascendis Pharma (ASND) stock rises after releasing impressive 5-year Phase 2 data for its hypoparath

The Touchstone Mid Cap Growth Fund (Class A Shares, Load Waived) outperformed its benchmark, the Rus

Ascendis Pharma A/S (NASDAQ:ASND) today announced 5-year (Week 266) data from its Phase 2 PaTH Forwa

– Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% re

COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno

Ascendis Pharma is initiated with a buy rating, reflecting its transition to a durable, commercial-s

Citigroup analyst Eric Joseph initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rati

Evercore ISI Group analyst Josh Schimmer maintains Ascendis Pharma (NASDAQ:ASND) with a Outperfor

Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raise

Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript

Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and l

Ascendis Pharma (NASDAQ:ASND) reported quarterly earnings of $0.32 per share which beat the analyst

- Q1 2026 revenue of €197 million for YORVIPATH ® and €44 million for SKYTROFA ® - More than 1,000 n

COPENHAGEN, Denmark, May 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today annou

COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today ann

COPENHAGEN, Denmark, April 21, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today ann

Assetmark Inc. raised its holdings in Ascendis Pharma A/S (NASDAQ: ASND) by 48.1% in the undefined q

Ascendis Pharma A/S (NASDAQ:ASND) today announced the commencement of trading of its ordinary shares

COPENHAGEN, Denmark, April 20, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today ann

B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and rai

Wedbush analyst Yun Zhong reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintain

 - Ordinary shares expected to commence trading on Nasdaq on April 20, 2026 following exchange of al

- Ordinary shares expected to commence trading on Nasdaq on April 20, 2026 following exchange of all

- Unprecedented improvements in arm span observed with TransCon CNP and TransCon hGH combination the

Ascendis Pharma A/S (NASDAQ:ASND) today announced that YUVIWEL (navepegritide; developed as TransCon

- YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric pat

Ascendis Pharma A/S (Nasdaq: ASND) today announced positive Week 52 topline results from New InsiGHT

Ascendis Pharma A/S (NASDAQ:ASND) today announced new data from its pivotal ApproaCH Trial showing t

RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raise

Ascendis Pharma shares rise after FDA approves Yuviwel, a weekly treatment for children with achondr

The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP ov

BridgeBio stock rises after Phase 3 trial shows its drug helped children with achondroplasia grow fa

Amy Raskin, CIO at Chevy Chase Trust, named Ascendis Pharma (ASND) as her final trade on CNBC's

BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly hal

Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quart